Evidence map›Paper›PMID 36191033›Full record

ArticlePLoS computational biology2022

Variant calling enhances the identification of cancer cells in single-cell RNA sequencing data.

William Gasper, Francesca Rossi, Matteo Ligorio, Dario Ghersi

Abstract read
In one paragraph

Article in PLoS computational biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

William GasperSchool of Interdisciplinary Informatics, University of Nebraska at Omaha, Omaha, Nebraska, United States of America.
Francesca RossiDepartment of Surgery, University of Texas Southwestern, Dallas, Texas, United States of America.
Matteo LigorioDepartment of Surgery, University of Texas Southwestern, Dallas, Texas, United States of America.
Dario GhersiSchool of Interdisciplinary Informatics, University of Nebraska at Omaha, Omaha, Nebraska, United States of America.ORCID 0000-0002-0630-0843

Funding

Targeting tumor architecture as a novel therapeutic strategy for pancreatic cancerR37CA242070 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Matteo Ligorio · 2021 to 2026
$2.8M
NCI NIH HHS R37 CA242070
6 · The paper itself

Abstract

Single-cell RNA-sequencing is an invaluable research tool that allows for the investigation of gene expression in heterogeneous cancer cell populations in ways that bulk RNA-seq cannot. However, normal (i.e., non tumor) cells in cancer samples have the potential to confound the downstream analysis of single-cell RNA-seq data. Existing methods for identifying cancer and normal cells include copy number variation inference, marker-gene expression analysis, and expression-based clustering. This work aims to extend the existing approaches for identifying cancer cells in single-cell RNA-seq samples by incorporating variant calling and the identification of putative driver alterations. We found that putative driver alterations can be detected in single-cell RNA-seq data obtained with full-length transcript technologies and noticed that a subset of cells in tumor samples are enriched for putative driver alterations as compared to normal cells. Furthermore, we show that the number of putative driver alterations and inferred copy number variation are not correlated in all samples. Taken together, our findings suggest that augmenting existing cancer-cell filtering methods with variant calling and analysis can increase the number of tumor cells that can be confidently included in downstream analyses of single-cell full-length transcript RNA-seq datasets.

Indexed as

DNA Copy Number VariationsNeoplasmsCluster AnalysisHigh-Throughput Nucleotide SequencingHumansRNARNA-SeqSequence Analysis, RNASingle-Cell AnalysisRNA

Identifiers

PMID36191033
PMCPMC9560611

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.